BEGIN:VCALENDAR VERSION:2.0 PRODID:-//wp-events-plugin.com//7.2.3.1//EN TZID:Europe/Helsinki X-WR-TIMEZONE:Europe/Helsinki BEGIN:VEVENT UID:248@inflames.utu.fi DTSTART;TZID=Europe/Helsinki:20230427T120000 DTEND;TZID=Europe/Helsinki:20230427T130000 DTSTAMP:20230424T063433Z URL:https://inflames.utu.fi/events/frontiers-of-science-prof-jason-sheltze r-2/ SUMMARY:CANCELLED: Frontiers of Science: Prof. Jason Sheltzer DESCRIPTION:\nCANCELLED\n\nSpring 2023 program\n\nProf. Jason Sheltzer\, Ya le School of Medicine\, USA\nMischaracterized anti-cancer agents and their true targets\nHost: Jukka Westermarck (jukwes@utu.fi)\n\nCoffee and sandw ich served at 11:45\n\nThe Sheltzer Lab studies the genetic changes that d rive cancer progression and cause developmental disabilities. The group is particularly interested in a condition called aneuploidy – a state in w hich cells gain or lose whole chromosomes. Aneuploidy is found in more tha n 90% of human tumors and is the most common cause of miscarriage and inte llectual disability\, but its effects on cell physiology are poorly unders tood. We apply a variety of complementary technologies\, including chromos ome engineering\, CRISPR/Cas9 mutagenesis\, and single cell sequencing\, i n order to develop new ways to model aneuploidy and to better understand i ts cellular and organismal consequences. The genetic alterations that occu r during tumorigenesis re-wire the underlying architecture of cancer cells and create certain cancer “dependencies”: genes and pathways that are required for cancer cell growth but that are dispensable in normal tissue . Drugs that inhibit the function of a cancer dependency can serve as pote nt therapeutic agents. Using CRISPR/Cas9\, the Sheltzer Lab is working to identify novel cancer dependencies\, and to improve the characterization o f the drugs that target them.\n\n \;\n\nSelected publications\n\nSchuk ken KM\, Sheltzer JM. 2022. Extensive protein dosage compensation in aneup loid human cancers. Genome Res. 32:1254-1270\n\nSmith JC\, Sheltzer JM. 20 22. Genome-wide identification and analysis of prognostic features in huma n cancers. Cell Rep. 38:110569\n\nChen WC\, Zhou J\, Sheltzer JM\, Kinney JB\, McCandlish DM. 2021. Field-theoretic density estimation for biologica l sequence space with applications to 5' splice site diversity and aneuplo idy in cancer. Proc Natl Acad Sci U S A. 118:e2025782118\n\nVasudevan A\, Schukken KM\, Sausville EL\, Girish V\, Adebambo OA\, Sheltzer JM. 2021. A neuploidy as a promoter and suppressor of malignant growth. Nat Rev Cancer . 21:89-103\n\nLin A\, Sheltzer JM. 2020. Discovering and validating cance r genetic dependencies: approaches and pitfalls. Nat Rev Genet. 21:671-682 \n\nSmith JC\, Sheltzer JM. 2018. Systematic identification of mutations a nd copy number alterations associated with cancer patient prognosis. Elife . 7:e39217\n\n \;\n\nGeneral information\n\n You can download all spr ing 2023 FoS-seminars in your calendar from here: https://seafile.utu.fi/d /4a0b831f23ef420786b0/\n Registration is not needed for the on-site semin ars\n Participation list is circulated in the audience\n If you are a st udent and later wish to get a certificate of attendance from the Frontier of Science seminars\, please print out this seminar diary and after the se minar ask the BioCity coordinator to sign it\n Please note that any audio or video recording of the seminars is strictly forbidden.\n\n \; ATTACH;FMTTYPE=image/jpeg:https://inflames.utu.fi/wp-content/uploads/2023/ 01/sheltzer400x400.jpg CATEGORIES:Tapahtumat END:VEVENT BEGIN:VTIMEZONE TZID:Europe/Helsinki X-LIC-LOCATION:Europe/Helsinki BEGIN:DAYLIGHT DTSTART:20230326T040000 TZOFFSETFROM:+0200 TZOFFSETTO:+0300 TZNAME:EEST END:DAYLIGHT END:VTIMEZONE END:VCALENDAR